ABOUT this BLOG and How to use it
WELCOME to Stu's Views and MS News e-Newsletter Ô
Key-Note: Our live MS educational seminars average approx 65 people per educational program and SINCE our first program in February 2010, we have hosted more than 118 educational programs. Most locations are in Florida and we have now added educational events in Georgia, Alabama and the Carolinas.
Register at our website to receive our globally transmitted Multiple Sclerosis e-newsletter, currently being received in more than (90) Countries.
Visit MS Views and News.org
Be Empowered with MS News and Information
Scroll to view All the resources found on the left side of this blog. Need to find information, use our 'search by topic' tool.
Thursday, October 25, 2012
Wednesday, October 24, 2012
Ezose Sciences Forms Alliance with Fast Forward to Discover Biomarkers to Diagnose Multiple Sclerosis
PINE BROOK, N.J.--(BUSINESS WIRE)--Ezose Sciences Inc. today announced an alliance with Fast Forward, LLC, a subsidiary of the National Multiple Sclerosis Society, to use Ezose’s GlycanMap® technology in the discovery of biomarkers to help diagnose multiple sclerosis (MS) and improve disease management.
Make way Batman and Spiderman - five new comic book superheroes with the unlikely names of Axon, Gastro, Skinderella, Pump and Chi are helping children around the world understand the complexities of multiple sclerosis - a condition which can baffle leading medical specialists.
The superhero characters are the brainchild of Dr Kate Hersov and Dr Kim Chilman-Blair - paediatric doctors who became increasingly frustrated at the lack of good educational resources for children suffering chronic illness, or for children whose parents were affected by such illness.
Their initiative has received some impressive backing - even the eminent British Medical Journal has called their comics a 'revolutionary medium' for children to learn about disease and disability. The BMJ notes that comics can convey educational messages about serious subjects in a fun and engaging way.
There five superheroes, each a 'specialist' in a different part of the body, take children on an adventurous journey around Mediland - a living, moving planet shaped like the human body.
The multiple sclerosis offering is part of a growing portfolio of comic books, each targeted for a different disease or clinical procedure. More than 30 titles have now been translated into 17 languages and distributed in 35 countries. The comics are aimed at children between the ages of 8 and 15.
If you would like, you can comment to our blog posts
A new study in mice where researchers replicated a rare type of immune cell in the lab and then infused it back into the body, is raising hope for a new treatment for severe autoimmune diseases such as multiple sclerosis and rheumatoid arthritis.
The researchers, from Duke University Medical Center in the US, write about their work on a type of B cell, in a paper that was published online in Nature at the weekend.
B CellsB cells are immune cells that create antibodies to attack unwanted pathogens like bacteria and viruses.
The type that the researchers on this study focused on are known as regulatory B cells or B10, after interleukin-10 (IL-10), a cell-signalling protein that the cells use.
B10 cells help control immune response and limit autoimmunity, which is where the immune system attacks the body's own healthy tissue as if it were an unwanted pathogen.
Although there aren't many of them, B10 cells play a key role in controlling inflammation: they limit normal immune response during inflammation, thus averting damage to healthy tissue.
Regulating Immune Response Is a Highly Controlled ProcessStudy author Thomas F. Tedder is a professor of immunology at Duke. He says in a statement that we are only just beginning to understand these recently discovered B10 cells.
He says these regulatory B cells are important because they "make sure an immune response doesn't get carried away, resulting in autoimmunity or pathology".
"This study shows for the first time that there is a highly controlled process that determines when and where these cells produce IL-10," he adds.
What they DidFor their study, Tedder and colleagues used mice to study how B10 cells produce IL-10. For IL-10 production to start, the B10 cells have to interact with T cells, which are involved in switching on the immune system.
They found B10 cells only react to certain antigens. They found that binding to these antigens makes the B10 cells turn off some of the T cells (when they come across the same antigen). This stops the immune system from harming healthy tissue.
This was a new insight into the function of B10 cells that spurred the researchers to see if they could take this further: what if it were possible to use this cellular control mechanism to regulate immune responses, particularly in respect of autoimmunity?
Replicating Large Numbers Outside the BodyB10 cells however are not common, they are extremely rare. So Tedder and colleagues had to find a way to make a ready supply of them outside the body.
They found a way to isolate the B10 cells without damaging their ability to control the immune responses. And they found a way to replicate them in large numbers, as Tedder explains:
Tuesday, October 23, 2012
Monday, October 22, 2012
Intercontinental Hotel Doral - 2505 NW 87th Avenue, Miami,, FL 33172
each time-slot allows for Q&A Sessions
10:00 a.m Physician Panel - Bladder Issues; Psychological (Family issues) and Pain Management - Presenters: Harvey Samowitz, MD, Rick Harris, MD , Antonio Mesa, D.O.
EMD Serono, Questcor, Genentech, Pfizer, Genzyme, Polar Products, Medtronic, Infinity Research, Teva Neuroscience, Acorda Therapeutics, Neuroscience Center of Florida, Biogen-Idec, DMR Mobility, Bioness, Cafe Ala Carte, Novartis, GigerMD and The MS Foundation
October 22, 2012
“I’m very pleased to be launching this groundbreaking international clinical trial here in Tasmania,” said Minister Collins. “It is great that Tasmanian patients will not only contribute to this research, but could also be among the first to benefit from its results.”
Test might someday help doctors determine who has aggressive disease earlier